Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 7/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151866 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| SCHEMBL12437619 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| SCHEMBL29952931 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| SCHEMBL6480162 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| SCHEMBL4040707 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| SCHEMBL993042 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| Hydrochloric Acid SCHEMBL11149903 | 0.98 | SLC1A2 (0.41) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| Hydrochloric Acid SCHEMBL8385290 | 0.98 | SLC1A2 (0.41) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| Hydrochloric Acid SCHEMBL2157333 | 0.98 | SLC1A2 (0.41) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| Hydrochloric Acid SCHEMBL19064846 | 0.98 | SLC1A2 (0.41) | SLC1A2SLC1A1PKMBLMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-116390742-A | Cyclic chemokine-9 derivatives | 拜耳公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20160272964-A1 | Method for Producing Peptide Library, Peptide Library, and Screening Method | THE UNIVERSITY OF TOKYO (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-2850072-B1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9365549-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20150252023-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150218538-A1 | Methods and Compositions for Modulating G-Alpha-Q Signaling | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| US-9066944-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| WO-2015095301-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | IRM LLC (BM) | 2015-06-25 | — | — | WO | disclosed |
| US-20130287731-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-31 | — | — | US | disclosed |
| US-20050009808-A1 | Azabicyclo compound matrix metalloprotease inibitor and skin preparation | SHISEIDO CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | SLC1A2 4743/4885SLC1A1 4584/4885PKM 2766/4885 |
| US-20130287731-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HCCS | SLC1A2 4330/4885SLC1A1 3060/4885PKM 3042/4885 |
| US-20050009808-A1 | Azabicyclo compound matrix metalloprotease inibitor and skin preparation | MMP1, MMP16, MMP9 | SLC1A2 2894/4885SLC1A1 3482/4885PKM 4744/4885 |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | CMKLR1, CMKLR2, CCL2 | SLC1A2 3862/4885SLC1A1 3131/4885PKM 3023/4885 |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | SLC1A2 1997/4885SLC1A1 1742/4885PKM 3271/4885 |
| US-20150252023-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HCCS | SLC1A2 4330/4885SLC1A1 3060/4885PKM 3042/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | SLC1A2 4743/4885SLC1A1 4584/4885PKM 2766/4885 |
| US-20160031903-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | SLC1A2 3554/4885SLC1A1 3692/4885PKM 1231/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | SLC1A2 2546/4885SLC1A1 2099/4885PKM 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.